^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Enshuxing (enlonstobart)

    i
    Other names: SYSA 1802, SG001, SG 001, SYSA1802, SG-001, SYSA-1802
    Associations

    News

    Trials
    Company:
    CSPC Pharma, Sumgen Biotech
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6d
    An open-label, multicenter, phase II study to evaluate the efficacy and safety of SYS6010 combined with enlonstobart in the recurrent or metastatic head and neck squamous cell carcinoma (ChiCTR2500112871)
    P2, N=70, Not yet recruiting, Shanghai East Hospital, Tongji University(Shanghai East Hospital); Shanghai East Hospital, Tongji University(Shanghai East Hospital)
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Enshuxing (enlonstobart) • SYS6010
    6d
    Phase II/III Trial of SYS6010 plus Enlonstobart Injection ± Chemotherapy in Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ChiCTR2500112440)
    P2/3, N=737, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    EGFR expression
    |
    cisplatin • paclitaxel • 5-fluorouracil • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • leucovorin calcium • Enshuxing (enlonstobart) • SYS6010
    6d
    A single-Arm, Open-Label Ib/II Study of Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma(PTCL) (ChiCTR2500111610)
    P1/2, N=43, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P1/2 trial
    |
    Duoenda (mitoxantrone liposomal) • Enshuxing (enlonstobart)
    6d
    Phase I/II clinical study of SYS6043 combined with PD-1/PD-L1 inhibitor ± chemotherapy in the treatment of advanced solid tumor participants (ChiCTR2500112838)
    P1/2, N=622, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P1/2 trial
    |
    cisplatin • carboplatin • gemcitabine • Tevimbra (tislelizumab-jsgr) • pemetrexed • etoposide IV • Hetronifly (serplulimab) • Enshuxing (enlonstobart)
    11d
    SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=70, Recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    Enshuxing (enlonstobart) • SYS6010
    25d
    A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer (clinicaltrials.gov)
    P2/3, N=490, Not yet recruiting, Shanghai JMT-Bio Inc.
    New P2/3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cisplatin • 5-fluorouracil • capecitabine • oxaliplatin • anbenitamab (KN026) • Enshuxing (enlonstobart)
    2ms
    Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) (clinicaltrials.gov)
    P1/2, N=43, Not yet recruiting, Sun Yet-Sen University Cancer Center
    New P1/2 trial
    |
    Duoenda (mitoxantrone liposomal) • Enshuxing (enlonstobart)
    2ms
    Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer (clinicaltrials.gov)
    P1/2, N=116, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • paclitaxel • Lenvima (lenvatinib) • Enshuxing (enlonstobart)
    2ms
    Phase 1b Multicenter Study of SG001, a Humanized Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors. (PubMed, Drug Des Devel Ther)
    The safety profile was well tolerated. ClinicalTrials.gov identifier: NCT03852823.
    Clinical • P1 data • Journal
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    Enshuxing (enlonstobart)
    2ms
    SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P2 trial
    |
    Enshuxing (enlonstobart) • SYS6010
    2ms
    A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. (clinicaltrials.gov)
    P2/3, N=737, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P2/3 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    EGFR expression
    |
    cisplatin • paclitaxel • 5-fluorouracil • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • Enshuxing (enlonstobart) • SYS6010
    3ms
    A Phase II Clinical Study of SYS6002 in combination with SG001 in patients with advanced urothelial cancer and other advanced solid tumor (ChiCTR2500107496)
    P2, N=148, Recruiting, Fudan University Shanghai Cancer Center; CSPC Megalith Biopharmaceutical Co., Ltd..
    New P2 trial
    |
    Enshuxing (enlonstobart)